- Home
- ANAB
ANAB
AnaptysBio Inc.
as 06-20-2025 4:00pm EST
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 621.1M | IPO Year: | 2017 |
| Target Price: | $44.25 | AVG Volume (30 days): | 775.6K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.21 - $41.31 | Next Earning Date: | 08-04-2025 |
| Revenue: | $111,872,000 | Revenue Growth: | 387.20% |
| Revenue Growth (this year): | -26.61% | Revenue Growth (next year): | 24.39% |
Latest AnaptysBio Inc. News
ANAB Breaking Stock News: Dive into ANAB Ticker-Specific Updates for Smart Investing
MT Newswires
17 days ago
Sector Update: Health Care Stocks Mixed Premarket Wednesday
MT Newswires
17 days ago
HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target
MT Newswires
18 days ago
AnaptysBio Reports Durable Responses, Favorable Safety for Rosnilimab in Arthritis Trial
GlobeNewswire
18 days ago
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
GlobeNewswire
25 days ago
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
Insider Monkey
a month ago
AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now
Simply Wall St.
a month ago
Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results
Simply Wall St.
a month ago
AnaptysBio First Quarter 2025 Earnings: Beats Expectations
Compare ANAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANAB AnaptysBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.